What antiviral therapy is recommended for a patient with confirmed influenza and an estimated glomerular filtration rate of 98 mL/min/1.73 m²?

Antiviral Treatment for Influenza with Normal Renal Function

Start oseltamivir 75 mg orally twice daily for 5 days as soon as possible, regardless of whether this patient is high-risk or otherwise healthy. 1

Treatment Algorithm

With a GFR of 98 mL/min/1.73 m², this patient has normal renal function and requires no dose adjustment for any neuraminidase inhibitor.

Decision Points Based on Patient Risk Status

If the patient meets ANY high-risk criteria:

• Hospitalized with influenza
• Severe or progressive illness
• Chronic medical conditions or immunocompromised
• Age <2 years or ≥65 years
• Pregnant or within 2 weeks postpartum

→ Must treat immediately with oseltamivir 75 mg twice daily for 5 days 1

If the patient is otherwise healthy without risk factors:

→ Can consider treatment with oseltamivir 75 mg twice daily for 5 days 1

The 2019 IDSA guidelines provide strong (A-1) evidence that treatment should begin as soon as possible with a single neuraminidase inhibitor, not combination therapy.

Alternative Neuraminidase Inhibitors (Normal Renal Function)

If oseltamivir is unavailable or contraindicated:

• Inhaled zanamivir: 10 mg (two 5-mg inhalations) twice daily for 5 days

  • Avoid in patients with underlying airway disease 2

• IV peramivir: Single 600 mg dose

  • Useful when oral/inhaled routes unavailable

• Baloxavir marboxil: Emerging option showing superior viral load reduction 2, 3, 4

  • WHO conditionally recommends for high-risk patients with non-severe influenza 3, 4
  • Resistance variants can emerge 2

Critical Timing Consideration

Treatment is most effective when started within 48 hours of symptom onset, though hospitalized patients should receive treatment regardless of illness duration 1. When initiated within 24 hours, oseltamivir reduces illness duration by 37-40% compared to placebo 5.

Duration of Treatment

• Standard duration: 5 days for uncomplicated influenza 1
• Extended duration: Consider longer treatment if:
  • Immunocompromised
  • Hospitalized with severe lower respiratory disease
  • Pneumonia or ARDS present 1

Common Pitfalls to Avoid

Do NOT:

• Use higher than FDA-approved doses routinely 1
• Combine multiple neuraminidase inhibitors 1
• Add corticosteroids unless indicated for other reasons 1
• Prescribe antibiotics unless bacterial coinfection is suspected 1

Monitor for bacterial coinfection if:

• Initial presentation with severe disease (extensive pneumonia, respiratory failure, hypotension)
• Clinical deterioration after initial improvement
• Failure to improve after 3-5 days of antiviral treatment 1

Renal Dosing Reference (For Completeness)

While not needed for this patient (GFR 98), oseltamivir requires dose adjustment when GFR <60 mL/min. Standard dosing applies for GFR ≥60 mL/min.